- Home
- GORO vs AGEN Comparison
GORO vs AGEN Comparison
Compare GORO & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GORO
- AGEN
- Stock Information
- Founded
- GORO 1998
- AGEN 1994
- Country
- GORO United States
- AGEN United States
- Employees
- GORO N/A
- AGEN N/A
- Industry
- GORO Precious Metals
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GORO Basic Materials
- AGEN Health Care
- Exchange
- GORO Nasdaq
- AGEN Nasdaq
- Market Cap
- GORO 86.1M
- AGEN 87.7M
- IPO Year
- GORO N/A
- AGEN 2000
- Fundamental
- Price
- GORO $0.70
- AGEN $5.72
- Analyst Decision
- GORO Strong Buy
- AGEN Buy
- Analyst Count
- GORO 1
- AGEN 4
- Target Price
- GORO $1.25
- AGEN $13.00
- AVG Volume (30 Days)
- GORO 1.6M
- AGEN 1.3M
- Earning Date
- GORO 08-05-2025
- AGEN 08-07-2025
- Dividend Yield
- GORO N/A
- AGEN N/A
- EPS Growth
- GORO N/A
- AGEN N/A
- EPS
- GORO N/A
- AGEN N/A
- Revenue
- GORO $59,378,000.00
- AGEN $99,524,000.00
- Revenue This Year
- GORO $68.69
- AGEN $12.69
- Revenue Next Year
- GORO $19.92
- AGEN N/A
- P/E Ratio
- GORO N/A
- AGEN N/A
- Revenue Growth
- GORO N/A
- AGEN N/A
- 52 Week Low
- GORO $0.12
- AGEN $1.38
- 52 Week High
- GORO $0.77
- AGEN $18.74
- Technical
- Relative Strength Index (RSI)
- GORO 62.98
- AGEN 64.51
- Support Level
- GORO $0.53
- AGEN $4.34
- Resistance Level
- GORO $0.77
- AGEN $5.22
- Average True Range (ATR)
- GORO 0.05
- AGEN 0.43
- MACD
- GORO 0.00
- AGEN -0.00
- Stochastic Oscillator
- GORO 68.81
- AGEN 95.17
About GORO Gold Resource Corporation
Gold Resource Corp is a producer of metal concentrates that contain gold, silver, copper, lead, and zinc in Oaxaca, Mexico. . It targets low capital expenditure projects with the potential for generating high returns on capital. The company's two pipeline projects are; Don David Gold at Oaxaca, Mexico, and Back Forty at Michigan, United States of America. The Company has two reporting segments, based on geographic regions. Oaxaca, Mexico represents the Company's only operating segment with a production stage property. The Company's other reporting segment is Michigan, U.S.A., with an exploration stage property.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).